|
Initial survival outcomes for the AGITG GAP study – a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC). |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Medtronic |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Specialised Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck Serono; Novartis; Pfizer; Roche; Sanofi; Specialised Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Cochlear; CSL Limited; ResMed; Sirtex Medical |
Honoraria - GlaxoSmithKline; Sanofi |
Consulting or Advisory Role - Roche; Specialised Therapeutics |
Research Funding - Celgene (Inst); Genentech (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Ipsen; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Confident Health Care |
Stock and Other Ownership Interests - Confident Health Care |
Consulting or Advisory Role - Merck Serono |
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - Specialised Therapeutics |
Travel, Accommodations, Expenses - Ipsen; Merck Serono |
|
|
Honoraria - Sirtex Medical |
Consulting or Advisory Role - Sirtex Medical |
Travel, Accommodations, Expenses - Sirtex Medical |
|
|
Research Funding - Specialised Therapeutics (Inst) |
|
|
Stock and Other Ownership Interests - Sirtex Medical |
Research Funding - Amgen (Inst); Celgene (Inst); pfizer (Inst) |